Incident cases within the acute myeloid leukaemia market are believed to have reached 23,497 in 2012, with close to half of the incident cases occurring in the US.
The growth of incident cases in the US is the highest amongst all markets at 2.29% per year, whereas the 5EU (France, Germany, Italy, Spain, and the UK) has a slightly slower growth rate of 1.33% per year from 2012-2022.
Acute myeloid leukaemia (AML) is a rare cancer that accounts for a disproportionally high number of cancer-related deaths (O'Donnell et al., 2012). The disease is more common in the elderly and is slightly more common in men than in women. Acute myeloid leukaemia grows at a fast pace and is found in the blood and bone marrow.
Prevalent cases of AML are nearly identical in numbers to incident cases, thereby underlining the lethality and poor long-term survival of the disease. Development of more effective therapies, particularly for elderly patients, would improve survival and increase disease prevalence.
Globally the numbers of elderly people, 60 years and above are growing and it is expected that this age group will cross the 1.3 billion mark in 2017. Hence the acute myeloid leukaemia market will also grow. Many AML products are in the pipeline or in different clinical phases that will bring a change in disease treatment.
Leading market players in the acute myeloid leukaemia therapeutics market accounted for almost 70-80% of the market share last years. Some big companies in the therapeutics market are Bristol-Myers Squibb, Novartis International AG, Roche, Genmab A/S, and GlaxoSmithKline Pharmaceuticals Limited.
In the future, manufacturing companies such as Pfizer are expected to enter this market, but will hold a major share.
For more information on the acute myeloid leukaemia market, see the latest research: Acute Myeloid Leukaemia Market
Follow us on Twitter @CandMResearch
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.